Media stories about Sequenom (NASDAQ:SQNM) have been trending somewhat negative on Thursday, Accern Sentiment Analysis reports. Accern scores the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Sequenom earned a news sentiment score of -0.01 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 44.8497505078251 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Sequenom Company Profile
Sequenom, Inc is a life sciences company. The Company serves patients and physicians by providing early patient management information. The Company operates through Sequenom Laboratories segment. It conducts its business as a molecular diagnostics clinical laboratory located in San Diego, California and Raleigh-Durham, North Carolina.
Receive News & Ratings for Sequenom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sequenom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.